For the Inventor, By the Inventor

Enter assignee name

Nippon Chemiphar Co., Ltd.

USPTO Granted Patents = 132

CIPO Patents = 11

EPO Patents = 32

Trademarks = 3

Forward Citations = 951

Loading Chart...

Loading Chart...

179 inventors (with patents filed for the assignee):

Mitsuo Masaki (31 out of 36 patents)

Shogo Sakuma (23 out of 23 patents)

Tomio Yamakawa (23 out of 24 patents)

4. Toshiyasu Imai (17 out of 17 patents)

5. Yutaka Nomura (15 out of 15 patents)

6. Yasuo Fujimoto (15 out of 24 patents)

7. Kunio Kobayashi (14 out of 14 patents)

8. Kazuhide Inoue (14 out of 15 patents)

9. Toshihiro Takahashi (14 out of 53 patents)

10. Masatoshi Ushioda (13 out of 13 patents)

11. Atsushi Tendo (11 out of 12 patents)

12. Toshiro Kamishiro (11 out of 11 patents)

13. Seiichiro Masui (10 out of 10 patents)

14. Masaru Satoh (10 out of 10 patents)

15. Daisuke Saito (9 out of 41 patents)

Core Competencies:

Renal Protection

Morphinan Derivative

P2X4 Receptor Antagonist

Diabetic Peripheral Neuropathy

Calcium Channel Blocker

Peroxisome Proliferator-Activated Receptor

Giant Cell Tumors

Dementia Treatment

GPR119 Agonist

Xanthine Oxidase Inhibitors

Opioid Delta Receptor Agonist

Cancer Resistance

132 patents: Sort by Forward Citations

1. 12324793 - Method for renal protection (2025-06-10),

2. 12233071 - Medicament for treating cough (2025-02-25),

3. 12202830 - Method for producing morphinan derivative (2025-01-21),

4. 12116351 - P2X4 receptor antagonist (2024-10-15),

5. 12109209 - Use of morphinan derivatives for treatment of opioid delta receptor agonist-related disease (2024-10-08),

6. 12090158 - Medicine for diabetic peripheral neuropathy (2024-09-17),

7. 12085560 - Biochemical reaction substrate with sloping flow passage to absorber and analyzer therefore (2024-09-10),

8. 11918589 - Medicament for treatment of multiple sclerosis (2024-03-05),

9. 11666582 - Medicament for treating cough (2023-06-06),

10. 11643411 - Morphinan derivative (2023-05-09),

11. 11633392 - Use of morphinan derivative for therapeutic treatment of opioid delta receptor agonist-related disease (2023-04-25),

12. 11434207 - P2X4 receptor antagonist (2022-09-06),

13. 11420944 - Voltage-dependent t-type calcium channel blocker (2022-08-23),

14. 11370761 - Voltage-dependent T-type calcium channel inhibitor (2022-06-28),

15. D953570 - Reagent cartridge (2022-05-31),

Established in 1948, Nippon Chemiphar Co., Ltd. is a Japanese pharmaceutical company engaged in the research, development, manufacture, and sale of pharmaceutical products. With a strong focus on innovative solutions, Nippon Chemiphar aims to contribute to the well-being of people globally. The company continually strives to enhance its product portfolio, manufacturing processes, and technologies to deliver safe and effective medications. By investing in cutting-edge research and collaborative partnerships, Nippon Chemiphar remains committed to providing high-quality healthcare solutions to meet the evolving needs of patients worldwide.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Jan 6 2026

132 Patents

#405 in Tokyo

#914 in Japan

#5,941 in the World

Nippon Chemiphar Co., Ltd.

Forward Citations = 951

179 inventors:

Mitsuo Masaki (31 out of 36 patents)

Shogo Sakuma (23 out of 23 patents)

Tomio Yamakawa (23 out of 24 patents)

4. Toshiyasu Imai (17 out of 17 patents)

5. Yutaka Nomura (15 out of 15 patents)

Please report any incorrect information to support@idiyas.com

Loading…